
Jarushka Naidoo
@drjnaidoo
Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University
ID: 972549291867889666
https://scholar.google.com/citations?user=MSEo30cAAAAJ&hl=en 10-03-2018 19:06:35
5,5K Tweet
10,10K Takipçi
1,1K Takip Edilen

Stage III ALK+ NSCLC: consolidation ALK TKI v Durva v Obs JTO & JTO CRR: -67pts, ALKi=15 Durva=30 obs=22 -mrwPFS favors ALKi (NR, 95%CI 22.7-NR) v durva (11.3m HR 0.12 p=0.006) v obs (7.2m HR=0.04 p<0.0001) Small n, but useful OncoAlert Amin Nassar, MD #LCSM jto.org/article/S1556-…